RARβ Promoter Methylation as an Epigenetic Mechanism of Gene Silencing in Non-small Cell Lung Cancer

2015 ◽  
pp. 29-38 ◽  
Author(s):  
A. Dutkowska ◽  
A. Antczak ◽  
D. Pastuszak-Lewandoska ◽  
M. Migdalska-Sęk ◽  
K. H. Czarnecka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gene Silencing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Small Cell ◽  
Epigenetic Mechanism ◽  
Small Cell Lung

scholarly journals Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines

2020 ◽  
Vol 21 (13) ◽  
pp. 4595
Author(s):  
Victoria Sarne ◽  
Samuel Huter ◽  
Sandrina Braunmueller ◽  
Lisa Rakob ◽  
Nico Jacobi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Small Cell ◽  
Marker Genes ◽  
Specific Gene ◽  
Small Cell Lung ◽  
The Impact

Specific gene promoter DNA methylation is becoming a powerful epigenetic biomarker in cancer diagnostics. Five genes (CDH1, CDKN2Ap16, RASSF1A, TERT, and WT1) were selected based on their frequently published potential as epigenetic markers. Diagnostic promoter methylation assays were generated based on bisulfite-converted DNA pyrosequencing. The methylation patterns of 144 non-small-cell lung cancer (NSCLC) and 7 healthy control formalin-fixed paraffin-embedded (FFPE) samples were analyzed to evaluate the applicability of the putative diagnostic markers. Statistically significant changes in methylation levels are shown for TERT and WT1. Furthermore, 12 NSCLC and two benign lung cell lines were characterized for promoter methylation. The in vitro tests involved a comparison of promoter methylation in 2D and 3D cultures, as well as therapeutic tests investigating the impact of CDH1/CDKN2Ap16/RASSF1A/TERT/WT1 promoter methylation on sensitivity to tyrosine kinase inhibitor (TKI) and DNA methyl-transferase inhibitor (DNMTI) treatments. We conclude that the selected markers have potential and putative impacts as diagnostic or even predictive marker genes, although a closer examination of the resulting protein expression and pathway regulation is needed.

scholarly journals Clinical Significance of Aberrant Wnt7a Promoter Methylation in Human Non-Small Cell Lung Cancer in Koreans

2015 ◽  
Vol 30 (2) ◽  
pp. 155 ◽  
Author(s):  
Tae-Hyung Kim ◽  
Ji-Yong Moon ◽  
Sang-Heon Kim ◽  
Seung Sam Paik ◽  
Ho Joo Yoon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Small Cell ◽  
Small Cell Lung

Stimuli-responsive release and efficient siRNA delivery in non-small cell lung cancer by a poly(l-histidine)-based multifunctional nanoplatform

2020 ◽  
Vol 8 (8) ◽  
pp. 1616-1628 ◽  
Author(s):  
Menghao Shi ◽  
Jiulong Zhang ◽  
Ziyuan Huang ◽  
Yuying Chen ◽  
Shuang Pan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gene Silencing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Sirna Delivery ◽  
Small Cell ◽  
Proton Sponge ◽  
Stimuli Responsive ◽  
Small Cell Lung

A stimuli-responsive nanoplatform achieves successful intracellular siRNA delivery due to a proton sponge effect based on poly(l-histidine) and effective gene silencing in vivo.

scholarly journals RASSF1A Promoter Methylation and Kras2 Mutations in Non Small Cell Lung Cancer

Neoplasia ◽  
2003 ◽  
Vol 5 (4) ◽  
pp. 362-366 ◽  
Author(s):  
Jie Li ◽  
Zhongqiu Zhang ◽  
Zunyan Dai ◽  
Anthony P. Popkie ◽  
Christoph Plass ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Lentivirus-mediated gene silencing of NOB1 suppresses non-small cell lung cancer cell proliferation

2015 ◽  
Vol 34 (3) ◽  
pp. 1510-1516 ◽  
Author(s):  
WEIYI HUANG ◽  
WEIQING ZHONG ◽  
JUN XU ◽  
BENHUA SU ◽  
GUANGHUI HUANG ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Proliferation ◽  
Gene Silencing ◽  
Small Cell Lung Cancer ◽  
Cancer Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cancer Cell Proliferation ◽  
Lung Cancer Cell ◽  
Small Cell Lung

scholarly journals The Effects of Lentivirus-Mediated Gene Silencing of RARβ on the Stemness Capability of Non-Small Cell Lung Cancer

2021 ◽  
Vol 12 (12) ◽  
pp. 3468-3485
Author(s):  
Noor Hanis Abu Halim ◽  
Norashikin Zakaria ◽  
Kumitaa Theva Das ◽  
Juntang Lin ◽  
Moon Nian Lim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gene Silencing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1523
Author(s):  
Federico Pio Fabrizio ◽  
Angelo Sparaneo ◽  
Andrea Fontana ◽  
Tommaso Mazza ◽  
Paolo Graziano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cell ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Epigenetic Mechanism ◽  
Aberrant Methylation ◽  
Small Cell Lung

The silencing of SPARC (secreted protein acid and rich in cysteine) gene through methylation of its promoter region represents a common event in many solid tumors and it is frequently associated with tumor progression and an aggressive clinical outcome. Anyhow, the data concerning the epigenetic mechanism of SPARC deregulation and its prognostic value in lung cancer are still incomplete. We explored the aberrant methylation of SPARC and its effects in 4 non-small cell lung cancer (NSCLC) cell lines and 59 NSCLC tissues and correlated the methylation levels with clinical-pathological features and disease outcome of patients. In 3 out of 4 tumor cell lines high SPARC methylation levels were observed. An inverse correlation between the epigenetic silencing and SPARC expression was confirmed by 5-Aza-2′-deoxycytidine ((5-Aza-CdR) treatment that also significantly induced a reduction in cell viability, proliferation and tumor cell migration. In tissues, the DNA methylation levels of the SPARC gene were significantly lower in paired non-neoplastic lungs (NLs) and normal lungs distant from tumor (NLDTs) than in NSCLCs (p = 0.002 and p = 0.0034 respectively). A promoter hypermethylation was detected in 68% of squamous cell carcinoma (SqCCs, 17/25) and 56% of adenocarcinoma (ADCs, 19/34), with SqCC showing the highest levels of methylation. Higher SPARC methylation levels were significantly associated with higher mortality risk both in all NSCLCs early stage patients (Hazard Ratio, HR = 1.97; 95% Confidence Interval, CI: 1.32–2.93; p = 0.001) and in those with SqCC (HR = 2.96; 95% CI: 1.43–6.12; p = 0.003). Promoter methylation of SPARC gene should represent an interesting prognostic biomarker in NSCLC, with potential application in the squamous early-stage context. Further research in this setting on larger independent cohorts of lung patients with different histologies and stages of disease are warranted.

Sign in / Sign up

Export Citation Format

Share Document